]>
IRCT20220406054440N1 IRCT 2022-05-10 Gorgan University of Medical Sciences Comparison of mirtazapine and citalopram in the treatment of depression in patients with breast cancer Comparison of the effectiveness of mirtazapine and citalopram on general health and quality of life in patients with major depression and breast cancer in the oncology ward 2022-04-30 anticipated 42 Complete https://irct.ir/trial/63231 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: Divide into two groups with equal numbers by simple random method, Blinding description: Only treatment participants and Care providers are unaware of the allocation of study groups. 1-2 Major Depression, Breast Cancer, Mirtazapine, Citalopram. After the clinical interview, if there is a diagnosis of depression in the patient based on the DSM-V criteria, the patient enters the research project. After consultation with the hematology specialist, the patient will be randomly divided into one of the interventional categories of mirtazapine or citalopram. Patients in the mirtazapine group will receive 15 mg of mirtazapine daily, and patients in the citalopram group will receive 20 mg of citalopram daily. Patients in both groups will receive medication for 3 months and will be routinely asked about patient compliance during pre-scheduled visits and the results will be recorded in a pre-prepared checklist.. Yes - There is a plan to make this available What will be shared: Questionnaire sf-36 and questionnaire GHQ-28 When: starting in January 2023 To whom: people working in academic institutions Conditions: No additional explanation. Where to obtain: Dr.z.keyvanlou@gmail.com How to obtain: Send request email and personal details Comments:
public Dr. Zohreh Keyvanlou Shahrestanaki
5 Azar Street
gorgan Iran (Islamic Republic of) 4917763681 +98 17 3222 0561 Dr.z.keyvanlou@gmail.com Gorgan University of Medical Sciences scientific Zohreh Keyvanlou Shahrestanaki
5 Azar St. 5 Azar Hospital
gorgan Iran (Islamic Republic of) 4917763681 +98 17 3222 0561 Dr.z.keyvanlou@gmail.com Gorgan University of Medical Sciences Iran (Islamic Republic of) Females with breast cancer after radiotherapy surgery and undergoing chemotherapy or radiotherapy in stages 1 to 4 of disease progression Age over 18 years and under 65 years Middle school education level and higher Existence of major depression criteria based on DSM-V criteria 18 years 65 years Female C50 , F32 Malignant neoplasm of breast, major depression Treatment - Drugs After the clinical interview, if there is a diagnosis of depression in the patient based on the DSM-V criteria, the patient enters the research project. After consultation with the hematology specialist, the patient will be randomly divided into one of the interventional categories of mirtazapine or citalopram. Patients in the mirtazapine group will receive 15 mg of mirtazapine daily, and patients in the citalopram group will receive 20 mg of citalopram daily. Patients in both groups will receive medication for 3 months and will be routinely asked about patient compliance during pre-scheduled visits and the results will be recorded in a pre-prepared checklist. Quality of life, general health. Timepoint: One and three months after starting treatment. Method of measurement: Questionnaire GHQ-28 and SF-36. Gorgan University of Medical Sciences Approved 2021-07-25 Ethics committee of Golestan University of Medical Sciences 5 Azar St., 5 Azar Hospital, Psychiatric Department Gorgan Golestan Iran (Islamic Republic of)